Fortrea (FTRE) vs Personalis (PSNL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Fortrea (FTRE) has outperformed Personalis (PSNL) over the past year, gaining 120.8% versus a gain of 111.4%. Fortrea is the larger company by market cap ($1.96 billion vs $1.71 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FTRE | PSNL |
|---|---|---|
| Share price | $20.56 | $16.00 |
| Market cap | $1.96B | $1.71B |
| 1-day change | -1.06% | -0.19% |
| YTD return | +19.19% | +101.01% |
| 1-year return | +120.84% | +111.36% |
| 5-year return | — | -19.76% |
| Forward P/E | 17.96 | — |
| EPS (TTM) | $-0.91 | $-1.09 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.51 | $18.89 |
| 52-week low | $8.55 | $4.96 |
| Distance from 52-week high | -12.55% | -15.30% |
| Analyst consensus | buy | hold |
| Avg. price target upside | +1.31% | -5.19% |
| Average volume | 1.45M | 3.60M |
| Shares outstanding | 95.10M | 106.80M |
| Employees | 14,000 | 259 |
| Sector | Health Care | Health Care |
| Industry | Medical Specialities | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Fortrea
FTRE stock →Fortrea Holdings Inc., a contract research organization, provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide. It offers clinical pharmacology, such as clinical research units, external partnerships, project management, study design and monitoring, bioanalytics and biomarkers, pharmacokinetics, modeling and simulation, and biometrics; and clinical development, including phase I through IV clinical and real-world evidence studies, regulatory affairs, protocol design, operational planning, study and site start-up, patient recruitment, project management, comprehensive site and medical monitoring, data management and biostatistics, pharmacovigilance, medical writing, and mobile clinical services.
Health Care · Medical Specialities · 14,000 employees
About Personalis
PSNL stock →Personalis, Inc. develops, markets, and sells advanced cancer genomic tests and services in the United States and internationally.
Health Care · Medical Specialities · 259 employees
FTRE vs PSNL FAQ
Which is bigger, Fortrea or Personalis?
Fortrea (FTRE) is larger, with a market capitalization of $1.96B compared with $1.71B for Personalis (PSNL).
Which stock has performed better over the past year, FTRE or PSNL?
FTRE returned +120.84% over the past 12 months, compared with +111.36% for PSNL (price return, excluding dividends). Past performance does not predict future results.
Are Fortrea and Personalis in the same industry?
Yes. Both are classified in the Medical Specialities industry within the Health Care sector.